AstraZeneca rose about 2% before the market opened. Chronic lymphocytic leukemia treatment achieved good results
Market Information 29/07/2024 16:55
AstraZeneca (AZN.US) US stocks rose 1.7% to $79.46 in pre-market trading. In the news, the company said that the results of its Calquence drug for the treatment of chronic lymphocytic leukemia were favorable. The company said that Calquence showed statistically significant and clinically important improvements in progression-free survival in untreated adult patients in the Amplify Phase III trial in combination with venetoclax, with or without obinutuzumab.